• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    ORIC Pharmaceuticals (ORIC) Teams Up With Cancer Research UK, Is The 40% Undervaluation Case Intact?

    Simply Wall St·10/17/2026 22:38:55
    Listen to the news

    ORIC Pharmaceuticals collaboration with Cancer Research UK

    ORIC Pharmaceuticals (ORIC) drew fresh attention after signing a collaboration with Cancer Research UK to move its CIP2A-targeted candidate ORIC-259 into early clinical development, with Cancer Research UK funding and running initial studies.

    ORIC Pharmaceuticals has already seen investors react to the Cancer Research UK partnership, with the share price falling 3.29% over the last day but gaining 15.10% over 90 days and recording a year to date share price return of 51.16% as sentiment around its pipeline has shifted. Over a longer horizon the picture is mixed, with a 1 year total shareholder return that is down 3.36%, in contrast with a 3 year total shareholder return of 118.20% and a 5 year total shareholder return that is down 17.11%, which hints at momentum building recently after a much tougher earlier period for holders.

    Spot opportunities around ORIC Pharmaceuticals by scanning a curated 20 high quality undiscovered gems that could be building under-the-radar pipelines of their own.

    ORIC Pharmaceuticals now pairs a fresh Cancer Research UK deal with a share price that has already moved sharply this year. Do you lean into that momentum today, or wait for a cheaper shot at the story as the valuation section shows?

    Most Popular Narrative: 40% Undervalued

    On the most followed view, ORIC Pharmaceuticals screens as undervalued, with a fair value estimate of $20.67 against a last close of $12.35. This points to a market that is still wrestling with how to price late stage cancer assets funded into 2028.

    Cash of US$388m at the end of Q2 2026 with guidance that this funds operations into the second half of 2028, including the ongoing Himalayas-1 Phase III and a planned Phase III for enozertinib starting in early 2027, along with Bayer supplying darolutamide for Himalayas-1 at no cost while ORIC retains full rinzimetostat rights, provides capacity to advance late stage programs while potentially limiting near term equity dilution and supporting future net margins and earnings leverage if products reach market.

    See why 1 investors see ORIC Pharmaceuticals as 40% undervalued.

    Result: Fair Value of $20.67 (UNDERVALUED)

    Still, the bullish ORIC Pharmaceuticals story hinges on clean late stage data and smooth trial execution. Any safety scare or delay could quickly puncture that 40% undervaluation narrative.

    Find out about the key risks to this ORIC Pharmaceuticals narrative.

    Next Steps

    The bullish tone around ORIC Pharmaceuticals is only part of the picture, and the clock is already ticking for anyone weighing up the trade off between upside and risk. Before making a call, take a close look at the 4 important warning signs.

    Looking for more investment ideas beyond ORIC Pharmaceuticals?

    ORIC Pharmaceuticals may already be on your radar, but the strongest portfolios rarely rely on a single story. Use this moment to widen your opportunity set.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.